0
0.5
1
1.5
2+
Case
24%
Improvement
Relative Risk
c19 early.org/p
Tsai et al. Povidone-Iod.. for COVID-19 Prophylaxis
Favors povidone-iodine
Favors control
Iodine contrast exposure and incident COVID-19 infection
Retrospective 530,942 COVID-19 tests in the USA, showing lower incidence of cases with exposure to iodine contrast for imaging within the last 60 days.
risk of case, 23.7% lower , RR 0.76, p < 0.001 , NNT 48, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tsai et al., 1 Dec 2022, retrospective, USA, peer-reviewed, 11 authors, study period 1 March, 2020 - 31 December, 2020.
Contact:
angela.leung@va.gov.
Abstract: TYPE Original Research
PUBLISHED
01 December 2022
DOI 10.3389/fmed.2022.1033601
OPEN ACCESS
Iodine contrast exposure and
incident COVID-19 infection
EDITED BY
Reza Lashgari,
Shahid Beheshti University, Iran
REVIEWED BY
Perumal Arumugam Desingu,
Indian Institute of Science (IISc), India
Xiaojiong Jia,
Harvard Medical School, United States
*CORRESPONDENCE
Angela M. Leung
Angela.Leung@va.gov
SPECIALTY SECTION
This article was submitted to
Infectious Diseases: Pathogenesis
and Therapy,
a section of the journal
Frontiers in Medicine
RECEIVED 31 August 2022
ACCEPTED 18 November 2022
PUBLISHED 01 December 2022
CITATION
Tsai K, Inoue K, McClean M,
Kaunitz JD, Akiba Y, Lee ML,
Neverova NV, Currier JW, Ebrahimi R,
Bashir MT and Leung AM (2022)
Iodine contrast exposure and incident
COVID-19 infection.
Front. Med. 9:1033601.
doi: 10.3389/fmed.2022.1033601
COPYRIGHT
© 2022 Tsai, Inoue, McClean, Kaunitz,
Akiba, Lee, Neverova, Currier,
Ebrahimi, Bashir and Leung. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.
Karen Tsai1,2 , Kosuke Inoue3,4 , Michael McClean5 ,
Jonathan D. Kaunitz6,7,8 , Yasutada Akiba6,7 , Martin L. Lee9,10 ,
Natalia V. Neverova11,12 , Jesse W. Currier11,12 ,
Ramin Ebrahimi11,12 , Muhammad T. Bashir5 and
Angela M. Leung1,2*
1
Endocrinology, Diabetes, and Metabolism Section, Medical Service, Veterans Affairs Greater Los
Angeles Healthcare System, Los Angeles, CA, United States, 2 Division of Endocrinology, Diabetes,
and Metabolism, Department of Medicine, David Geffen School of Medicine, University of
California, Los Angeles, Los Angeles, CA, United States, 3 Department of Social Epidemiology,
Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4 Department of Internal Medicine, Ito
Hospital, Tokyo, Japan, 5 Research Service, Veterans Affairs Greater Los Angeles Healthcare System,
Los Angeles, CA, United States, 6 Gastroenterology Section, Medical Service, Veterans Affairs Greater
Los Angeles Healthcare System, Los Angeles, CA, United States, 7 Division of Gastroenterology,
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles,
Los Angeles, CA, United States, 8 Department of Surgery, David Geffen School of Medicine,
University of California, Los Angeles, Los Angeles, CA, United States, 9 Veterans Affairs Health
Services Research and Development, Center for the Study of Health Care Innovation,
Implementation, and Policy, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles,
CA, United States, 10 Department of Biostatistics, Fielding School of Public Health, University
of California, Los Angeles, Los Angeles, CA, United States, 11 Cardiology Section, Medical Service,
Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, United States, 12 Division
of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California,
Los Angeles, Los Angeles, CA, United States
Background: Iodine and particularly its oxidated forms have long been
recognized for its effective antiseptic properties. Limited in vitro and in vivo
data suggest..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit